A Call for Implementation of an Evidence-Based, Quality Improvement, Decompensated Cirrhosis Discharge Care Bundle in Australia
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patient Cohort and Auditing
2.2. Statistical Analysis
3. Results
Description of the Cohort
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Conflicts of Interest
References
- Australian Institute of Health and Welfare. Leading Cause of Premature Mortality in Australia Fact Sheet: Liver Disease; AIHW: Canberra, ACT, Australia, 2015.
- Fagan, K.J.; Zhao, E.Y.; Horsfall, L.U.; Ruffin, B.J.; Kruger, M.S.; McPhail, S.M.; O’Rourke, P.; Ballard, E.; Irvine, K.M.; Powell, E.E. Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: Time for change? Intern. Med. J. 2014, 44, 865–872. [Google Scholar] [CrossRef] [PubMed]
- Karlsen, T.H.; Sheron, N.; Zelber-Sagi, S.; Carrieri, P.; Dusheiko, G.; Bugianesi, E.; Pryke, R.; Hutchinson, S.J.; Sangro, B.; Martin, N.K.; et al. The EASL–Lancet Liver Commission: Protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2021, 399, 61–116. [Google Scholar] [CrossRef]
- European Association for The Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 2018, 69, 406–460. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arroyo, V.; Moreau, R.; Jalan, R. Acute-on-Chronic Liver Failure. N. Engl. J. Med. 2020, 383, 892–893. [Google Scholar]
- Moreau, R.; Jalan, R.; Gines, P.; Pavesi, M.; Angeli, P.; Cordoba, J.; Durand, F.; Gustot, T.; Saliba, F.; Domenicali, M.; et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013, 144, 1426–1437.e9. [Google Scholar] [CrossRef] [PubMed]
- Hernaez, R.; Solà, E.; Moreau, R.; Ginès, P. Acute-on-chronic liver failure: An update. Gut 2017, 66, 541–553. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Powell, E.E.; Skoien, R.; Rahman, T.; Clark, P.J.; O’Beirne, J.; Hartel, G.; Stuart, K.A.; McPhail, S.M.; Gupta, R.; Boyd, P.; et al. Increasing Hospitalization Rates for Cirrhosis: Overrepresentation of Disadvantaged Australians. eClinicalMedicine 2019, 11, 44–53. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jencks, S.F.; Williams, M.V.; Coleman, E.A. Rehospitalizations among Patients in the Medicare Fee-for-Service Program. N. Engl. J. Med. 2009, 360, 1418–1428. [Google Scholar] [CrossRef] [PubMed]
- Scaglione, S.J.; Metcalfe, L.; Kliethermes, S.; Vasilyev, I.; Tsang, R.; Caines, A.; Mumtaz, S.; Goyal, V.; Khalid, A.; Shoham, D.; et al. Early Hospital Readmissions and Mortality in Patients with Decompensated Cirrhosis Enrolled in a Large National Health Insurance Administrative Database. J. Clin. Gastroenterol. 2017, 51, 839–844. [Google Scholar] [CrossRef] [PubMed]
- Morales, B.P.; Planas, R.; Bartoli, R.; Morillas, R.M.; Sala, M.; Cabré, E.; Casas, I.; Masnou, H. Early hospital readmission in decompensated cirrhosis: Incidence, impact on mortality, and predictive factors. Dig. Liver Dis. 2017, 49, 903–909. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berman, K.; Tandra, S.; Forssell, K.; Vuppalanchi, R.; Burton, J.R.; Nguyen, J.; Mullis, D.; Kwo, P.; Chalasani, N. Incidence and Predictors of 30-Day Readmission Among Patients Hospitalized for Advanced Liver Disease. Clin. Gastroenterol. Hepatol. 2011, 9, 254–259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hayward, K.L.; Bansal, V.; Valery, P.C.; Irvine, K.M.; Wright, P.L.; Tallis, C.J.; Stuart, K.A.; Cottrell, W.N.; Martin, J.H.; Powell, E.E. Patient-oriented medication education intervention has long-term benefits for people with decompensated cirrhosis. Hepatol. Commun. 2022. [Google Scholar] [CrossRef] [PubMed]
- Biggins, S.W.; Angeli, P.; Garcia-Tsao, G.; Ginès, P.; Ling, S.C.; Nadim, M.K.; Wong, F.; Kim, W.R. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021, 74, 1014–1048. [Google Scholar] [CrossRef] [PubMed]
- Volk, M.L.; Tocco, R.S.; Bazick, J.; Rakoski, M.O.; Lok, A.S. Hospital Readmissions Among Patients with Decompensated Cirrhosis. Am. J. Gastroenterol. 2012, 107, 247–252. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Resar, R.; Griffin, F.A.; Haraden, C.; Nolan, T.W. Using Care Bundles to Improve Health Care Quality; IHI Innovation Series white paper; Institute for Healthcare Improvement: Cambridge, MA, USA, 2012. [Google Scholar]
- Smethurst, K.; Gallacher, J.; Jopson, L.; Majiyagbe, T.; Johnson, A.; Copeman, P.; Mansour, D.; McPherson, S. Improved outcomes following the implementation of a decompensated cirrhosis discharge bundle. Frontline Gastroenterol. 2021. [Google Scholar] [CrossRef]
- Gallacher, J.; Majiyagbe, T.; Jopson, L.; Johnson, A.; Coleman, P.; McPherson, S. P191 Use of a decompensated cirrhosis discharge care bundle improves outcomes in patient care. Gut 2021, 70, A142. [Google Scholar]
- British Society of Gastroenterology. Cirrhosis Discharge Bundle Long V1.1 BSG-BASL 25-08-2020. Available online: https://www.bsg.org.uk/wp-content/uploads/2020/08/Cirrhosis-discharge-bundle-long-V1.1-BSG-BASL-25-08-2020.pdf (accessed on 1 May 2021).
- Rodrigues, S.G.; Mendoza, Y.P.; Bosch, J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep. 2019, 2, 100063. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- European Association for The Study of The Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J. Hepatol. 2010, 53, 397–417. [Google Scholar] [CrossRef] [PubMed]
ICD-10 Code | N | Percent % |
---|---|---|
K70.3 Alcoholic cirrhosis of liver | 299 | 60.2 |
K75.8 Non-alcoholic steatohepatitis | 72 | 14.5 |
B18.2 Chronic viral hepatitis C | 47 | 9.5 |
C22.0 Hepatocellular carcinoma | 21 | 4.2 |
B18.1 Chronic viral hepatitis B | 12 | 2.4 |
Other | 46 | 9.2 |
Total | 497 | 100 |
ICD-10 Code | N | Percent % |
---|---|---|
G94.3 Hepatic encephalopathy | 80 | 16.1 |
I85.0 Esophageal variceal bleeding | 70 | 14.1 |
R18.0 Ascites | 40 | 8.0 |
K76.7 Hepatorenal syndrome | 12 | 2.4 |
Other | 114 | 22.9 |
Undetermined | 181 | 36.4 |
Total | 497 | 100 |
N | Percentage (%) | |
---|---|---|
Follow up post-discharge | ||
No follow-up appointment scheduled | 227 | (45.6%) |
Follow-up appointment scheduled | 270 | (54.3%) |
Alcohol misuse | ||
Alcohol consumption | 239 | (48.1%) |
Community follow up | 111 | (22.3%) |
Thiamine prescribed | 307 | (61.7%) |
Post-discharge referral to external agency | 23 | (4.6%) |
Reviewed by hospital alcohol team | 124 | (24.9%) |
Hepatic encephalopathy (HE) management | ||
HE present | 216 | (43.5%) |
Lactulose prescribed | 309 | (62.2%) |
Rifaximin prescribed | 201 | (40.4%) |
Both Lactulose and Rifaximin prescribed | 183 | (36.8%) |
Ascites management | ||
Diuretics prescribed | 365 | (73.4%) |
Spironolactone | 232 | (46.7%) |
Furosemide | 126 | (25.4%) |
Hydrochlorothiazide | 5 | (1.0%) |
Amiloride | 2 | (0.4%) |
Weight reported on discharge letter | 419 | (84.3%) |
Paracentesis performed before discharge | 221 | (44.4%) |
Paracentesis predicted interval not reported | 109 | (21.9%) |
Paracentesis scheduled at Western Sydney Local Health District (WSLHD) | 98 | (19.7%) |
Spontaneous bacterial peritonitis (SBP) | ||
History of SBP | 144 | (29.0%) |
Cotrimoxazole prescribed | 22 | (4.4%) |
Identified SPB organism | ||
Escherichia coli | 8.5% | |
Viridans streptococci | 1.9% | |
Staphylococcus aureus | 1.3% | |
Others | 4.1% | |
Unidentified organism | 84.2% | |
Varices | ||
Esophageal varices | 149 | (29.4%) |
Gastric varices | 19 | (3.8%) |
Grade of varices | ||
I | 46 | (9.3%) |
II | 53 | (10.7%) |
III | 39 | (7.8%) |
IV | 3 | (0.6%) |
Presence of red wale sign | 33 | (6.6%) |
Primary prophylaxis of portal hypertension | ||
Beta blockers prescribed | 170 | (34.2%) |
Beta blockers not prescribed | 323 | (64.9%) |
Amiloride | 106 | (21.3%) |
Spironolactone | 38 | (7.6%) |
Torsemide | 18 | (3.6%) |
Esophageal varices | 149 | (29.4%) |
Esophageal varices -ligation performed | 77 | (15.5%) |
Repeat esophagogastroscopy | 58 | (11.6%) |
Repeat EGD not performed | 439 | (88.3%) |
Repeat EDG interval (4 weeks) | 14 | (2.8%) |
Reasons for lack of primary prophylaxis | ||
Prophylaxis performed at another hospital | 3 | (0.6%) |
Prophylaxis previously performed | 75 | (15.1%) |
Nil mentioned | 419 | (84.3%) |
Secondary prophylaxis of portal hypertension | ||
Beta blocker prescribed | 156 | (31.3%) |
Repeat EGD for ligation | 67 | (13.4%) |
Renal function | ||
Reporting Creatinine, Sodium (Na), Potassium (K) levels in discharge letter | 450 | (90.5%) |
Frequency of Urea and Electrolytes(U&Es) in discharge letters—not reported | 46 | (9.25%) |
Diuretics reduction | ||
General practitioner | 39 | (7.84%) |
Specialist | 10 | (2.0%) |
Unknown | 1 | (0.2%) |
Unapplicable | 44 | (8.85%) |
Not to reduce | 403 | (81.0%) |
Pre-discharge Investigations | ||
Coagulation profile (Coags) | 488 | (98.1%) |
Liver function tests (LFTs) | 494 | (99.3%) |
Electrolytes, urea, creatinine (EUC) | 494 | (99.3%) |
Full blood count (FBC) | 494 | (99.3%) |
Alpha feto protein (AFP) | 111 | (22.33%) |
Treatment | ||
Present escalation and emergency plans | 76 | (15.2%) |
Palliative care reported in discharge letter | 21 | (4.2%) |
Palliative care referral | 25 | (5.0%) |
Liver transplant referral | 37 | (7.4%) |
Referral for Transjugular intrahepatic portosystemic stent-shunt (TIPSS) (per admission) | 73 | (14.6%) |
Qualified for TIPSS (per admission) | 106 | (21.3%) |
Patient Education | ||
Diagnosis was explained | 6 | (1.2%) |
Importance of alcohol abstinence (if applicable) | 3 | (0.6%) |
Explained current medications | 3 | (0.6%) |
Handing leaflets about cirrhosis | 0 | (0.0%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kalo, E.; Sheriff, N.; Isaac, M.; Baig, A.; Read, S.; Ahlenstiel, G. A Call for Implementation of an Evidence-Based, Quality Improvement, Decompensated Cirrhosis Discharge Care Bundle in Australia. Livers 2022, 2, 97-104. https://doi.org/10.3390/livers2020007
Kalo E, Sheriff N, Isaac M, Baig A, Read S, Ahlenstiel G. A Call for Implementation of an Evidence-Based, Quality Improvement, Decompensated Cirrhosis Discharge Care Bundle in Australia. Livers. 2022; 2(2):97-104. https://doi.org/10.3390/livers2020007
Chicago/Turabian StyleKalo, Eric, Nashwa Sheriff, Marina Isaac, Asma Baig, Scott Read, and Golo Ahlenstiel. 2022. "A Call for Implementation of an Evidence-Based, Quality Improvement, Decompensated Cirrhosis Discharge Care Bundle in Australia" Livers 2, no. 2: 97-104. https://doi.org/10.3390/livers2020007
APA StyleKalo, E., Sheriff, N., Isaac, M., Baig, A., Read, S., & Ahlenstiel, G. (2022). A Call for Implementation of an Evidence-Based, Quality Improvement, Decompensated Cirrhosis Discharge Care Bundle in Australia. Livers, 2(2), 97-104. https://doi.org/10.3390/livers2020007